Back to Gloucestershire Hospitals NHS Foundation Trust website

9: Nutrition and blood

Approved: 4 Oct 2017. Last amended: 16 Dec 2020.

On this page

9.1 Anaemias and some other blood disorders

9.1.1 Iron deficiency anaemia

9.1.1.1 Oral iron

Recommended

  • Ferrous fumarate 322mg tablets

    • Alternative

  • Ferrous sulfate 200mg tablets

    • Specific Indication

  • Ferrous fumarate liquid 140mg/5ml

    Patients unable to swallow iron tablets

  • Sodium feredetate liquid

    Neonate / Paediatric use

    • 9.1.1.2 Oral iron with folic acid

    Specific Indication

  • Ferrous fumarate (305mg) with folic acid (350mcg) Galfer FA®

    • 9.1.1.3 Parenteral iron

    Specific Indication

  • Cosmofer® (iron dextran)

    Cosmofer® guideline

    Sample Cosmofer® prescription chart

  • Diafer® (ferric derisomaltose)

    Renal dialysis patients only

  • Ferinject® (ferric carboxymaltose)

    Sample Ferinject® prescription chart

  • Monofer® (ferric derisomaltose)

    Sample Monofer® prescription chart

    • 9.1.2 Megaloblastic anaemia

    9.1.2.1 Folic Acid

    Recommended

  • Folic acid tablets

    • Specific Indication

  • Folic acid liquid

    Patients unable to swallow tablets

    • 9.1.2.2 Vitamin B12

    Vitamin B12 Deficiency Guideline

    Recommended

  • Cyanocobalamin 100mcg, 1mg tablets

    • Specific Indication

  • Hydroxocobalamin 1mg i.m. injection

    Where oral cyanocobalamin is unsuitable (as per local guideline)

    • 9.1.3 Hypoplastic, haemolytic and renal anaemias

    9.1.3.1 Erythropoeisis Stimulating Agents

    Recommended

  • Aranesp® (darbepoetin)
    • anaemia in people with cancer having chemotherapy, as per NICE TA323
    • anaemia associated with chronic kidney disease, as per NICE NG8
  • Mircera® (methoxy polyethylene glycol-epoetin beta)
    • anaemia associated with chronic kidney disease, as per NICE NG8

    • Specific Indication

  • Other erythropoeisis stimulating agents

    • 9.1.3.2 Iron Chelators

  • Deferasirox
  • Deferiprone
  • Desferrioxamine mesilate
  • Dexrazoxane

    • 9.1.3.3 Atypical haemolytic uraemic syndrome and paroxysmal nocturnal haemoglobinuria

  • Eculizumab

    As per NICE HST1

    • 9.1.4 Drugs Used in Platelet Disorders

  • Anagrelide

    Essential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugs

  • Eltrombopag

    Chronic immune (idiopathic) thrombocytopenic purpura, as per NICE TA293

  • Lusutrombopag

    Thrombocytopenia in people with chronic liver disease needing a planned invasive procedure, as per NICE TA617

  • Romiplostim

    Chronic immune (idiopathic) thrombocytopenic purpura, as per NICE TA221

    • 9.1.5 Drugs used in neutropenia

    Recommended

  • Filgrastim

    • Specific Indication

  • Lenograstim
  • Pegfilgrastim

    • 9.1.6 Drugs used to mobilise stem cells

  • Plerixafor

    • 9.2 Fluid and electrolyte imbalances

    9.2.1 Bicarbonate

    9.2.2 Calcium

    9.2.2.1 Hypocalcaemia

    9.2.2.2 Hypercalcaemia

    See also Section 6.6 - Drugs affecting bone metabolism

  • Cinacalcet
    • Secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy, as per NICE TA117
    • Primary hyperparathyroidism if surgery has been unsuccessful or is unsuitable, as per NICE NG132
  • Etelcalcetide
    • Secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy, where cinacalcet is unsuitable, as per NICE TA448

    • 9.2.3 Magnesium

    9.2.4 Phosphate

    9.2.4.1 Hypophosphataemia

    9.2.4.2 Hyperphosphataemia

    Specific Indication

  • Renacet®

    (Calcium acetate) tablets. Phosphate binder in renal impairment

    • 9.2.5 Potassium

    9.2.5.1 Hypokalaemia

    GHNHSFT Treatment Guideline – Hypokalaemia

    Recommended

  • Sando K® effervescent tablets (12mmol K+ per tablet)
  • Intravenous potassium

    Use pre-made infusion bags

    • Specific Indication

  • Kay Cee L® liquid (1mmol K+ per ml)

    Patients unable to tolerate Sando K

    • 9.2.5.2 Hyperkalaemia

    GHNHSFT Treatment Guideline – Hyperkalaemia

    Specific Indication

  • Sodium zirconium cyclosilicate

    Hyperkalaemia, as per NICE TA599

  • Patiromer

    Hyperkalaemia, as per NICE TA623

    • 9.2.6 Sodium

    9.3 Metabolic disorders

  • Elosulfase alfa

    Mucopolysaccharidosis type IVa, as per NICE HST2

  • Migalastat

    Fabry disease, as per NICE HST4

  • Eliglustat

    Type 1 Gaucher disease, as per NICE HST5

  • Asfotase

    Paediatric-onset hypophosphatasia, as per NICE HST6

  • Inotersen

    Hereditary transthyretin amyloidosis, as per NICE HST9

  • Patisiran

    Hereditary transthyretin amyloidosis, as per NICE HST10

  • Cerliponase alfa

    Neuronal ceroid lipofuscinosis type 2, as per NICE HST12

    • 9.4 Trace element deficiencies

    Not currently included in the Joint Formulary

    9.5 Nutrition

    Not currently included in the Joint Formulary

    9.6 Vitamin deficiencies

    9.6.1 Vitamin A

    9.6.2 Vitamin B

    9.6.3 Vitamin C

    9.6.4 Vitamin D

    GHNHSFT Vitamin D Treatment Guideline

    9.6.4.1 High Dose Colecalciferol

    Recommended

  • HuxD3®

    (colecalciferol 20,000iu) capsules

    • Specific Indication

  • Colecalciferol

    300,000iu in 1ml injection

    • 9.6.4.2 Low Dose Colecalciferol

  • Stexerol-D3®

    (colecalciferol 1,000iu) tablets

    • 9.6.4.3 Calcium with Vitamin D

  • Calci-D®

    (Calcium carbonate 2.5g [equiv. to calcium 1g] / colecalciferol 1,000iu) chewable tablets

    • 9.6.5 Vitamin E

    9.6.6 Vitamin K

    9.6.7 Multivitamin Preparations

    On this page

    Key

    Hospital / Specialist only

    Specialist initiation

    Treatment Guidelines

    Back to top
    BEST CARE FOR EVERYONE

    We use cookies to provide you with a better service. Carry on browsing if you’re happy with this or read more about our cookie policy and privacy policy.

    Dismiss